etylmetylhydroksypyrydyna succinate succinate succinate | Mexidol tablets 0.125 g, 50 pcs.

Latin name

Mexidolum

Release form

Tablets, coated with a white to white cream-colored shade, biconvex

in the cross section, 2 layers are visible: the inner (core) gray or cream-gray shade and the outer white or creamy white shade.



packaging 10 pcs - blister packagings (5) - packs of cardboard.

Pharmacological action

Mexidol® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotics (antipsychotics)).

The mechanism of action of Mexidol® is due to its antioxidant, antihypoxic and membrane protective effect. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improved synaptic transmission.

Mexidol® boosts dopamine levels in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (red blood cells and platelets) during hemolysis. It has a lipid-lowering effect, reduces the content of total cholesterol and low density lipoproteins.

Antistress action is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wakefulness cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various brain structures.

Mexidol® has a pronounced antitoxic effect in withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to remove cognitive impairment caused by prolonged intake of ethanol and its cancellation. Under the influence of Mexidol®, the effect of tranquilizing, antipsychotic, antidepressant, hypnotics and anticonvulsants is enhanced, which allows to reduce their doses and reduce side effects. Mexidol® improves the functional state of the ischemic myocardium. In conditions of coronary insufficiency, it increases the collateral blood supply to the ischemic myocardium, helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility with reversible cardiac dysfunction.

Pharmacokinetics

Absorption

With the introduction of Mexidol in doses of 400-500 mg Cmax in plasma is 3.5-4.0 μg / ml and is achieved within 0.45-0.5 hours.

Distribution of

After i / m administration, the drug is determined in blood plasma for 4 hours The average retention time of the drug in the body is 0.7-1.3 hours.

Excretion of

It is excreted in the urine mainly in a glucuronoconjugated form and in small amounts unchanged.

Indications

the consequences of acute cerebrovascular accidents, including after in the subcompensation phase as prophylactic courses

mild traumatic brain injury, consequences of traumatic brain injuries

encephalopathy of various origins (discirculatory, dysmetabolic, post-traumatic, mixed)

autonomic dystonia syndrome

pulmonary necrotizing neurotrophic neurotic disorders

conditions after acute intoxication with antipsychotics

asthenic conditions, as well as for the prevention of Itijah somatic diseases under the influence of extreme factors and

exposure to extreme stress (stress) factors.

coronary heart disease as part of the complex therapy

relief of withdrawal symptoms in alcoholism with a predominance of neurosis and vegetative-vascular disorders, post-withdrawal disorders

Contraindications

increased individual sensitivity to the drug

acute renal failure

acute liver failure.

Due to insufficient knowledge of the effect of the drug - childhood, pregnancy, breastfeeding.

Use during pregnancy and lactation

There have been no strictly controlled clinical trials of the safety of the drug MexidolВ® during pregnancy and lactation.

Composition

Active ingredient:

ethylmethylhydroxypyridine succinate (2-ethyl-6-methyl-3-hydroxypyridine succinate) - 125.0 mg

Excipients:

lactose monohydrate - 97.5 mg, 25.0 mg, ppm

magnesium stearate - 2.50 mg

Film coat:

opadra II white 33G28435 - 7.5 mg (hypromellose - 3.0 mg, titanium dioxide - 1.875 mg, lactose monohydrate - 1.575 mg, polyethylene glycol (macrogol) - 0.6 mg, triacetin - 0.45 mg)

Side effects

From the digestive system: rarely - nausea, dry mouth.

Other: rarely - allergic reactions.

The drug interaction

Mexidol® is combined with all drugs used to treat somatic diseases.

When used together, Mexidol® enhances the effects of benzodiazepine derivatives, antidepressants, anxiolytics, antiparkinsonian and anticonvulsants.

Mexidol® reduces the toxic effects of ethanol.

Overdose

Symptoms: possible drowsiness.

Storage conditions

In a dry, dark place at a temperature of no higher than 25 РC.

Keep out of the reach of children.

Expiration

3 years.

Do not use after the expiry date stated on the package

Deystvuyuschee substances

Эtylmetylhydroksypyrydyna succinate

Dosage form

tablets dosage form

tablets

Farmasoft, Russia